Form D · Biotechnology

Corridor Pharmaceuticals, Inc.

Baltimore, MD · CIK 0001471665

Offering snapshot reported Jan 31, 2013 · SEC filing

Reported sold
$1.56M
Offering amount: $1.8M
Investors reported
9
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 18, 2013
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 31, 2013Initial$1,558,429No comparison9SEC filing
Jun 24, 2010Initial$13,012,475No comparison8SEC filing
Sep 10, 2009Initial$4,161,000No comparison8SEC filing

Offering details

Securities
Debt
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-191139

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
NoneNone

Source: Form D, filed Jan 31, 2013. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Leonard Patrick Gage Director
Philip Goelet Director
Peter Greenleaf Director
Brian Halak Director
David King Director
Gary Lessing Director, Executive
Stephen Roth Director, Executive
Zev Scherl Director
Anne Shiflett Executive
Mark Strobeck Director, Executive
Peter Suzdak Executive
Geeta Vemuri Director
Philippe Walker Director
Phillipe Walker Director
David Zopf Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1122 Kenilworth Drive Suite 401
Baltimore, MD, 21204